Spring Bank Pharmaceuticals Unternehmenskultur

Mr. Donald Mitchell, also known as Don, MBA has been a Vice President of Operations and Corporate Development at Spring Bank Pharmaceuticals, Inc. since March 2011. Mr. Mitchell served as the Chief Commercial Officer at Spring Bank Pharmaceuticals, Inc. since December 2008 until March 2011. He served as Executive Director of Corporate Development at Idenix Pharmaceuticals; Director of Marketing & Strategic Planning at Amgen; Principal Consultant of Pricewaterhouse Coopers and Director of Marketing & Business Development at Novartis.

Mr. Jonathan P. Freve, also known as Jon, CPA, has been the Chief Financial Officer and Treasurer of Spring Bank Pharmaceuticals, Inc. since January 2015 and served as its Vice President of Finance since February 2015. Mr. Freve served as Secretary of Spring Bank Pharmaceuticals, Inc. since January 2015. Mr. Freve joined the Spring Bank Pharmaceuticals, Inc. with more than 16 years of progressive experience in the life science and technology industries ranging from venture-backed start-ups to publicly traded companies. He served as the Senior Director of Finance of Santaris Pharma A/S, which was acquired by F. Hoffmann-La Roche Ltd. He held Controller positions at two international public companies. He began his career at the Financial Accounting Standards Board (FASB) and PricewaterhouseCoopers, where he worked in the audit and transaction services practices. Over his career, he has supported and worked on numerous successful initial public offerings, secondary offerings, mergers and acquisitions, ERP implementations and a variety of complex accounting matters. Mr. Freve is a Certified Public Accountant in Massachusetts and holds a Bachelor's degree in Business Administration from the University of Massachusetts Amherst.

Dr. Radhakrishna P. Iyer, also known as Kris, PhD, FRSC Co-Founded Spring Bank Pharmaceuticals, Inc. in 2002 and has been its Chief Scientific Officer since 2002. Dr. Iyer founded Spring Bank Technologies Inc. and serves as its Vice President of Research & Development. He served as Founding Scientist and Vice President of Discovery of Origenix Technologies Inc., and Senior Scientist & Director of Discovery of Hybridon Inc. He has over 15 years experience in nucleic acids chemistry and antisense technology, drug discovery and development. He was Research Scientist at NIH. He has been a Director of Spring Bank Pharmaceuticals, Inc since 2002. He served as Member of Scientific Advisory Board of Topigen Pharmaceuticals, Inc. Dr. Iyer was elected fellow of Royal Society of Chemistry, UK in 2004 and UICT Diamond Jubilee Distinguished Fellow in Pharmaceutical Sciences, University of Mumbai, in 2003. He was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M. D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and Research at FDA/NIH. He received his BS, with honors, in chemistry and physics, his BS degrees in the Technology of Pharmaceuticals and Fine Chemicals and his MS in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received a PhD degree in Pharmaceutical Sciences from the University of the Pacific in Stockton, California and carried out postdoctoral work at the Oak Ridge National Laboratory and at Johns Hopkins University.

Donald Mitchell serves as the VP, Operations & Corporate Development for Spring Bank Pharmaceuticals. Donald started at Spring Bank Pharmaceuticals in October of 2008. Donald is based in the Greater Boston Area.

Jonathan Freve serves as the Chief Financial Officer and Treasurer for Spring Bank Pharmaceuticals, Inc.. Jonathan started at Spring Bank Pharmaceuticals, Inc. in December of 2014. Jonathan is based in the Greater Boston Area.